Product Name: Testolactone
Synonyms: 1,2,3,4,4a,4b,7,9,10,10a-decahydro-2-hydroxy-2,4b-dimethyl-7-oxo-1-phenanthren;1,2-dehydrotestololactone;1,2-didehydro-testololacton;17alpha-oxo-d-homo-1,4-androstadiene-3,17-dione;17-secoandrosta-1,4-dien-17-oicacid,13-hydroxy-3-oxo-1delta-lactone;1-dehydrotestololactone;delta(1)-dehydrotestolactone;delta(1)-dehydrotestololactone
CAS: 968-93-4
MF: C19H24O3
MW: 300.39
EINECS: 213-534-6
Product Categories: Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Steroids
Mol File: 968-93-4.mol

Testolactone Chemical Properties
Melting point  218-219°
alpha  D23 -45.6° (c = 1.24 in chloroform)
Boiling point  482.0±45.0 °C(Predicted)
density  1.17±0.1 g/cm3(Predicted)
CAS DataBase Reference 968-93-4(CAS DataBase Reference)
Safety Information
HS Code  2937290000
Hazardous Substances Data 968-93-4(Hazardous Substances Data)

Testolactone Usage And Synthesis
Uses Antineoplastic; non-selective steroidal aromatase inhibitor that prevents the conversion from androgen to estrogen. Used in in the treatment of familial male precocious puberty. An effective anti-tumor agent.
Uses Testolactone USP (Teslac) is used to treat Breast cancer.
General Description Testolactone, 13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acidΔ-lactone (Teslac),was originally synthesized as a possible anabolic steroid,considering its structural similarity to testosterone. The keystructural difference from anabolic steroids is the D-ring lactone instead of the typical cyclopentyl ring. Althoughconsidered in many texts an androgen or anabolic steroid (itis a Schedule III drug because of its classification as an anabolicsteroid), testolactone lacks androgenic effects in vivo.Its action is believed to be caused by irreversible inhibitionof aromatase. It is a relatively weak inhibitor of aromatase,but the irreversible nature of the inhibition can lead to prolongedeffects. Its relatively weak inhibition of aromataseand its undesirable dosage schedule (5×50-mg tabletsq.i.d.) give this older agent only limited use in breast cancertreatment because of better available options.

Product Name: Testolactone
Synonyms: 1,2,3,4,4a,4b,7,9,10,10a-decahydro-2-hydroxy-2,4b-dimethyl-7-oxo-1-phenanthren;1,2-dehydrotestololactone;1,2-didehydro-testololacton;17alpha-oxo-d-homo-1,4-androstadiene-3,17-dione;17-secoandrosta-1,4-dien-17-oicacid,13-hydroxy-3-oxo-1delta-lactone;1-dehydrotestololactone;delta(1)-dehydrotestolactone;delta(1)-dehydrotestololactone
CAS: 968-93-4
MF: C19H24O3
MW: 300.39
EINECS: 213-534-6
Product Categories: Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Steroids
Mol File: 968-93-4.mol

Testolactone Chemical Properties
Melting point  218-219°
alpha  D23 -45.6° (c = 1.24 in chloroform)
Boiling point  482.0±45.0 °C(Predicted)
density  1.17±0.1 g/cm3(Predicted)
CAS DataBase Reference 968-93-4(CAS DataBase Reference)
Safety Information
HS Code  2937290000
Hazardous Substances Data 968-93-4(Hazardous Substances Data)

Testolactone Usage And Synthesis
Uses Antineoplastic; non-selective steroidal aromatase inhibitor that prevents the conversion from androgen to estrogen. Used in in the treatment of familial male precocious puberty. An effective anti-tumor agent.
Uses Testolactone USP (Teslac) is used to treat Breast cancer.
General Description Testolactone, 13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acidΔ-lactone (Teslac),was originally synthesized as a possible anabolic steroid,considering its structural similarity to testosterone. The keystructural difference from anabolic steroids is the D-ring lactone instead of the typical cyclopentyl ring. Althoughconsidered in many texts an androgen or anabolic steroid (itis a Schedule III drug because of its classification as an anabolicsteroid), testolactone lacks androgenic effects in vivo.Its action is believed to be caused by irreversible inhibitionof aromatase. It is a relatively weak inhibitor of aromatase,but the irreversible nature of the inhibition can lead to prolongedeffects. Its relatively weak inhibition of aromataseand its undesirable dosage schedule (5×50-mg tabletsq.i.d.) give this older agent only limited use in breast cancertreatment because of better available options.